297 related articles for article (PubMed ID: 11522187)
1. HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers.
Gorse GJ; Patel GB; Belshe RB;
AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1175-89. PubMed ID: 11522187
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida.
Salmon-Céron D; Excler JL; Finkielsztejn L; Autran B; Gluckman JC; Sicard D; Matthews TJ; Meignier B; Valentin C; El Habib R; Blondeau C; Raux M; Moog C; Tartaglia J; Chong P; Klein M; Milcamps B; Heshmati F; Plotkin S
AIDS Res Hum Retroviruses; 1999 May; 15(7):633-45. PubMed ID: 10331442
[TBL] [Abstract][Full Text] [Related]
3. Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1(SF-2) recombinant GP120.
Gorse GJ; Patel GB; Mandava MD; Arbuckle JA; Doyle TM; Belshe RB;
Vaccine; 2001 Feb; 19(13-14):1806-19. PubMed ID: 11166906
[TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus type 1 envelope-specific cytotoxic T lymphocytes response dynamics after prime-boost vaccine regimens with human immunodeficiency virus type 1 canarypox and pseudovirions.
Arp J; Rovinski B; Sambhara S; Tartaglia J; Dekaban G
Viral Immunol; 1999; 12(4):281-96. PubMed ID: 10630788
[TBL] [Abstract][Full Text] [Related]
5. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers.
Evans TG; Keefer MC; Weinhold KJ; Wolff M; Montefiori D; Gorse GJ; Graham BS; McElrath MJ; Clements-Mann ML; Mulligan MJ; Fast P; Walker MC; Excler JL; Duliege AM; Tartaglia J
J Infect Dis; 1999 Aug; 180(2):290-8. PubMed ID: 10395842
[TBL] [Abstract][Full Text] [Related]
6. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
AIDS Vaccine Evaluation Group 022 Protocol Team
J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
[TBL] [Abstract][Full Text] [Related]
7. Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy.
Ferrari G; Berend C; Ottinger J; Dodge R; Bartlett J; Toso J; Moody D; Tartaglia J; Cox WI; Paoletti E; Weinhold KJ
Blood; 1997 Sep; 90(6):2406-16. PubMed ID: 9310492
[TBL] [Abstract][Full Text] [Related]
8. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
Belshe RB; Gorse GJ; Mulligan MJ; Evans TG; Keefer MC; Excler JL; Duliege AM; Tartaglia J; Cox WI; McNamara J; Hwang KL; Bradney A; Montefiori D; Weinhold KJ
AIDS; 1998 Dec; 12(18):2407-15. PubMed ID: 9875578
[TBL] [Abstract][Full Text] [Related]
9. Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine. NIAID AIDS Vaccine Evaluation Group.
Sabbaj S; Mulligan MJ; Hsieh RH; Belshe RB; McGhee JR
AIDS; 2000 Jul; 14(10):1365-74. PubMed ID: 10930151
[TBL] [Abstract][Full Text] [Related]
10. An algorithm for evaluating human cytotoxic T lymphocyte responses to candidate AIDS vaccines.
Carruth LM; Greten TF; Murray CE; Castro MG; Crone SN; Pavlat W; Schneck JP; Siliciano RF
AIDS Res Hum Retroviruses; 1999 Jul; 15(11):1021-34. PubMed ID: 10445814
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.
Belshe RB; Stevens C; Gorse GJ; Buchbinder S; Weinhold K; Sheppard H; Stablein D; Self S; McNamara J; Frey S; Flores J; Excler JL; Klein M; Habib RE; Duliege AM; Harro C; Corey L; Keefer M; Mulligan M; Wright P; Celum C; Judson F; Mayer K; McKirnan D; Marmor M; Woody G;
J Infect Dis; 2001 May; 183(9):1343-52. PubMed ID: 11294665
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study.
Cao H; Kaleebu P; Hom D; Flores J; Agrawal D; Jones N; Serwanga J; Okello M; Walker C; Sheppard H; El-Habib R; Klein M; Mbidde E; Mugyenyi P; Walker B; Ellner J; Mugerwa R;
J Infect Dis; 2003 Mar; 187(6):887-95. PubMed ID: 12660934
[TBL] [Abstract][Full Text] [Related]
13. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene.
Egan MA; Pavlat WA; Tartaglia J; Paoletti E; Weinhold KJ; Clements ML; Siliciano RF
J Infect Dis; 1995 Jun; 171(6):1623-7. PubMed ID: 7769304
[TBL] [Abstract][Full Text] [Related]
14. Enhanced sensitivity of detection of cytotoxic T lymphocyte responses to HIV type 1 proteins using an extended in vitro stimulation period for measuring effector function in volunteers enrolled in an ALVAC-HIV phase I/II prime boost vaccine trial in Thailand.
Kantakamalakul W; De Souza M; Karnasuta C; Brown A; Gurunathan S; Birx D; Thongcharoen P; Taveg T
AIDS Res Hum Retroviruses; 2004 Jun; 20(6):642-4. PubMed ID: 15242541
[TBL] [Abstract][Full Text] [Related]
15. Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160.
Fleury B; Janvier G; Pialoux G; Buseyne F; Robertson MN; Tartaglia J; Paoletti E; Kieny MP; Excler JL; Rivière Y
J Infect Dis; 1996 Oct; 174(4):734-8. PubMed ID: 8843210
[TBL] [Abstract][Full Text] [Related]
16. Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies.
Gorse GJ; Patel GB; Mandava MD; Belshe RB
Vaccine; 1999 Dec; 18(9-10):835-49. PubMed ID: 10580197
[TBL] [Abstract][Full Text] [Related]
17. Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses.
Chen X; Rock MT; Hammonds J; Tartaglia J; Shintani A; Currier J; Slike B; Crowe JE; Marovich M; Spearman P
J Virol; 2005 May; 79(9):5537-47. PubMed ID: 15827168
[TBL] [Abstract][Full Text] [Related]
18. Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele.
Ferrari G; Neal W; Ottinger J; Jones AM; Edwards BH; Goepfert P; Betts MR; Koup RA; Buchbinder S; McElrath MJ; Tartaglia J; Weinhold KJ
J Immunol; 2004 Aug; 173(3):2126-33. PubMed ID: 15265949
[TBL] [Abstract][Full Text] [Related]
19. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
Gorse GJ; Corey L; Patel GB; Mandava M; Hsieh RH; Matthews TJ; Walker MC; McElrath MJ; Berman PW; Eibl MM; Belshe RB
AIDS Res Hum Retroviruses; 1999 Jan; 15(2):115-32. PubMed ID: 10029244
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 vaccination administered intramuscularly can induce both systemic and mucosal T cell immunity in HIV-1-uninfected individuals.
Musey L; Ding Y; Elizaga M; Ha R; Celum C; McElrath MJ
J Immunol; 2003 Jul; 171(2):1094-101. PubMed ID: 12847284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]